We Venture Capital invests in Capitainer and Zetta Genomics

We Venture Capital has announced investments in Sweden's Capitainer and UK-based Zetta Genomics

Investment in Capitainer

We Venture Capital lead Series A round of 6.7 m EUR in Capitainer AB, a Swedish start-up developing point of need diagnostics microsampling solutions. We Venture Capital invest alongside Sciety and Sciety Venture Partners.

The new investment enables Capitainer to increase efforts in sales and production. During the next 18 months, Capitainer will build out production capacity, initiate key collaborations and solidify sales of its microsampling products in EU and US. The investment is the first scale-up round after years of successful product development.

We are very impressed by the product performance and what the Capitainer team has achieved the last few years. The product portfolio is disruptive and innovative and demonstrate very solid data. We look forward to supporting Capitainer on their future journey. Louise Warme, Head of We Venture Capital

The company operations in Sweden today and are scaling up by building an agent and distribution network in Europe, as well as sales channels in the US.

This investment enables us to focus our sales and marketing efforts in EU and in US. We are very happy to work with We Venture Capital who will be an active investor for Capitainer. The timing is perfect as we are now expanding sales due to the progress we have had in 2023 in Diabetes monitoring, self-sampling of Kidney transplanted patients and solutions for Drugs of Abuse and Heavy Metal screening. Christopher Aulin, CEO of Capitainer

About Capitainer

Capitainer AB is a Swedish MedTech company that develops and sells patient-centric solutions for self-sampling of blood, plasma, and urine. Founded in 2016, Capitainer has developed unique technologies for collecting and drying exact volumes of fluid within easy-to-use sampling cards. These cards may be sent as standard post to relevant testing laboratories, thus bypassing the need for cold chain logistics and specialised packaging. Capitainer’s products are market-leading with respect to precision and accuracy, with demonstrated equal performance to established pipetting methods. The products are applicable within several market segments, including but not limited to, clinical biomarkers, therapeutic drug monitoring, genomics, drug abuse and doping testing, and R&D and clinical studies.

Investment in Zetta Genomics

We Venture Capital lead the seed extension round of 4.3m EUR in Zetta Genomics.

The new investment enables Zetta to increase its go to market and scale-up activities. During the next years, Zetta will focus on converting its strong pipeline into customers resulting in growth to its annual recurring revenue. The investment is the first scale-up round after years of successful product development.

We are deeply impressed with Xetabase, the platform developed by Zetta. The solution unlocks the data potential of genomics through enabling real-time scalable use & tertiary analysis of large complex datasets. The platform is continuously updated with the latest scientific breakthroughs keeping all patient samples active. We look forward to supporting Zetta on their future journey. Louise Warme, Head of We Venture Capital

Zetta is a British company that has developed a genomic informatics platform, providing tertiary analysis of NGS testing. The technology enables analysis at scale with the ability to host hundreds of thousands of NGS on the platform, which are updated real time for new clinically relevant information.

Zetta Genomics is already making a difference to patients as XetaBase empowers clinicians to make faster and more accurate diagnoses at scale. With our second seed funding round now finalised, we are scaling and innovating our technologies and enhancing customer focus. Ignacio Medina, Zetta Genomics CEO

We Venture Capital invest alongside Nina Capital, Cambridge Enterprise Nova Capital and other institutional investors.

About Zetta Genomics

Zetta Genomics unleashes the power of precision medicine to improve health outcomes for millions of patients around the world.

Founded in 2017, Zetta Genomics is a fast-scaling genomic data technology company headquartered in Cambridge, UK, with offices in Valencia, Spain. A spin-out from the University of Cambridge and Genomics England, Zetta Genomics concentrates genomic, big data and start-up expertise to deliver data management fit for the precision medicine era.

The company’s XetaBase genomic data management platform simplifies tertiary genomic data analysis – aggregating, indexing and enriching secondary data at scale and speed – to accelerate discovery, diagnosis and the delivery of genomic medicine.

For more information on Zetta, please contact zetta@milkandhoneypr.com or visit www.zettagenomics.com.

About We Venture Capital

We Venture Capital is a specialized fund investing in diagnostics, as well as tools and digital solutions in the diagnostics area. Being the corporate investment arm of Werfen, a worldwide leader in specialized diagnostics, We Venture Capital is an active investor, leveraging the network and knowledge from Werfen to the benefit of our investments.

We invest in and partner with early-stage startups close to market entry or early scale-ups, working close with our portfolio to support their growth over time. We are firm believers of technical advancement as a means to improve patient outcomes and revolutionize healthcare.